vs
Dominari Holdings Inc.（DOMH）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是ARS Pharmaceuticals, Inc.的1.1倍（$30.1M vs $28.1M），ARS Pharmaceuticals, Inc.净利率更高（-147.1% vs -438.1%，领先291.0%），Dominari Holdings Inc.同比增速更快（220.4% vs -67.6%）
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
DOMH vs SPRY — 直观对比
营收规模更大
DOMH
是对方的1.1倍
$28.1M
营收增速更快
DOMH
高出288.0%
-67.6%
净利率更高
SPRY
高出291.0%
-438.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $28.1M |
| 净利润 | $-131.8M | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | -8.9% | -147.6% |
| 净利率 | -438.1% | -147.1% |
| 营收同比 | 220.4% | -67.6% |
| 净利润同比 | -12426.2% | -182.8% |
| 每股收益（稀释后） | $-6.94 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHSPRY
| Q4 25 | $30.1M | $28.1M | ||
| Q3 25 | $50.8M | $32.5M | ||
| Q2 25 | $34.1M | $15.7M | ||
| Q1 25 | $8.1M | $8.0M | ||
| Q4 24 | $9.4M | $86.6M | ||
| Q3 24 | $4.0M | $2.1M | ||
| Q2 24 | $6.2M | $500.0K | ||
| Q1 24 | $1.4M | $0 |
净利润DOMHSPRY
| Q4 25 | $-131.8M | $-41.3M | ||
| Q3 25 | $125.2M | $-51.2M | ||
| Q2 25 | $16.6M | $-44.9M | ||
| Q1 25 | $-32.5M | $-33.9M | ||
| Q4 24 | $1.1M | $49.9M | ||
| Q3 24 | $-4.2M | $-19.1M | ||
| Q2 24 | $-6.1M | $-12.5M | ||
| Q1 24 | $-5.4M | $-10.3M |
营业利润率DOMHSPRY
| Q4 25 | -8.9% | -147.6% | ||
| Q3 25 | -3.1% | -163.7% | ||
| Q2 25 | -57.0% | -302.9% | ||
| Q1 25 | -394.6% | -466.3% | ||
| Q4 24 | 0.4% | 54.5% | ||
| Q3 24 | -79.1% | -1051.6% | ||
| Q2 24 | -44.3% | -3068.0% | ||
| Q1 24 | -205.2% | — |
净利率DOMHSPRY
| Q4 25 | -438.1% | -147.1% | ||
| Q3 25 | 246.4% | -157.4% | ||
| Q2 25 | 48.7% | -285.6% | ||
| Q1 25 | -400.5% | -425.7% | ||
| Q4 24 | 11.4% | 57.7% | ||
| Q3 24 | -104.2% | -925.0% | ||
| Q2 24 | -99.1% | -2503.2% | ||
| Q1 24 | -398.0% | — |
每股收益（稀释后）DOMHSPRY
| Q4 25 | $-6.94 | $-0.41 | ||
| Q3 25 | $7.27 | $-0.52 | ||
| Q2 25 | $1.12 | $-0.46 | ||
| Q1 25 | $-3.02 | $-0.35 | ||
| Q4 24 | $0.21 | $0.52 | ||
| Q3 24 | $-0.67 | $-0.20 | ||
| Q2 24 | $-1.01 | $-0.13 | ||
| Q1 24 | $-0.91 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $69.4M | $114.3M |
| 总资产 | $112.9M | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资DOMHSPRY
| Q4 25 | $80.5M | $245.0M | ||
| Q3 25 | $176.2M | $288.2M | ||
| Q2 25 | $28.2M | $240.1M | ||
| Q1 25 | $18.9M | $275.7M | ||
| Q4 24 | $8.2M | $314.0M | ||
| Q3 24 | $7.2M | $204.6M | ||
| Q2 24 | $12.1M | $218.7M | ||
| Q1 24 | $7.1M | $223.6M |
总债务DOMHSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DOMHSPRY
| Q4 25 | $69.4M | $114.3M | ||
| Q3 25 | $210.2M | $147.7M | ||
| Q2 25 | $88.6M | $192.3M | ||
| Q1 25 | $42.4M | $229.0M | ||
| Q4 24 | $39.9M | $256.8M | ||
| Q3 24 | $38.3M | $201.0M | ||
| Q2 24 | $42.4M | $215.2M | ||
| Q1 24 | $47.7M | $223.9M |
总资产DOMHSPRY
| Q4 25 | $112.9M | $327.7M | ||
| Q3 25 | $223.4M | $372.8M | ||
| Q2 25 | $109.3M | $313.5M | ||
| Q1 25 | $52.3M | $327.3M | ||
| Q4 24 | $47.1M | $351.2M | ||
| Q3 24 | $43.4M | $217.6M | ||
| Q2 24 | $49.1M | $222.0M | ||
| Q1 24 | $52.2M | $227.6M |
负债/权益比DOMHSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOMHSPRY
| Q4 25 | $22.7M | $-43.5M | ||
| Q3 25 | $-4.9M | $-47.0M | ||
| Q2 25 | $-353.0K | $-39.6M | ||
| Q1 25 | $1.2M | $-40.7M | ||
| Q4 24 | $-16.7M | $42.0M | ||
| Q3 24 | $-4.7M | $-14.5M | ||
| Q2 24 | $1.4M | $-7.3M | ||
| Q1 24 | $-8.6M | $-6.7M |
自由现金流DOMHSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
自由现金流率DOMHSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
资本支出强度DOMHSPRY
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
现金转化率DOMHSPRY
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
